Clinical Roundup Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds July 31, 2026Vol.52 No.30
Clinical Roundup BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds July 31, 2026Vol.52 No.30
Clinical Roundup DNA atlas could power the next generation of AI drug discovery, Salk-led study finds July 31, 2026Vol.52 No.30
Clinical Roundup Engineered gut bacteria, BifidoSumIL-2, shows promise against pancreatic cancer July 31, 2026Vol.52 No.30
Clinical Roundup Moffitt-led team develops chemical approach to build safer precision medicines July 31, 2026Vol.52 No.30
Clinical Roundup Tecvayli + Talvey, Talvey + pomalidomide show significant survival benefit in earlier-line r/r MM, phase III trial shows July 24, 2026Vol.52 No.29
Clinical Roundup Next-gen CAR-T therapy shows “dramatic and rapid” regression of glioblastoma, Mass General phase I study finds July 24, 2026Vol.52 No.29
Clinical Roundup Retesting with at-home FIT tests is linked to earlier diagnoses, retrospective cohort study finds July 24, 2026Vol.52 No.29
Clinical Roundup Chemo resistance in ovarian cancer may be reversible with existing drugs, Wistar study finds July 24, 2026Vol.52 No.29
Clinical Roundup Biological sex linked to protein changes in lung adenocarcinoma and other cancers, Sanford Burnham Prebys study finds July 24, 2026Vol.52 No.29
